Evaluation of long-term efficacy and safety of transdermal XXXX in the treatment of chronic @entity158 .

@entity1 @entity3347 @entity390 @entity12046 @entity1887 @entity2147 @entity1576 @entity158 @entity1142 @entity3575 @entity734
The objective of this international, multicenter, open-label trial was to assess the efficacy and safety of up to 12 months of therapy with transdermal therapeutic system (TTS) @entity3575 in @entity1 (n = 532) with chronic @entity158 . The trial was completed by 301 (57%) of the @entity1 . The main outcome measures were @entity158 control assessment, global treatment satisfaction, @entity1 preference for TTS @entity3575 , and quality of life. The mean dose of transdermal @entity3575 ( @entity12046 ) increased from 48 to 90 microg/h during a period of 12 months. During treatment, on average 67% of @entity1 within the efficacy analysis group (n = 524) reported very good, good, or moderate @entity158 control. Global satisfaction (very good or good) was also stable at 42%. The majority (86%) of @entity1 reported a preference for @entity12046 over their previous treatment (P < .001, binomial test). Short Form 36 quality-of-life scores improved from baseline for @entity158 . The most frequent treatment-related adverse events were @entity390 (31%), @entity1142 (19%), and @entity2147 (18%). With regard to opioid-specific adverse events ( @entity1576 [< 1%], @entity1887 [< 1%], @entity734 [1%], and @entity3347 [3%]), these were extremely rare and, with the exception of @entity3347 , none was considered definitively related to the treatment. Long-term treatment with @entity12046 provided a stable degree of @entity158 control in the majority of @entity1 with moderate to severe chronic @entity158 . It was preferred by the majority of @entity1 compared with their previous opioid medication. Overall, long-term treatment with @entity12046 was generally well tolerated, particularly in view of the low incidence of potentially serious side effects such as @entity734 and @entity1576 . However, at present, it is important that @entity1 receiving @entity12046 should still be subject to careful assessment and monitoring.
